HIND
Price
$4.93
Change
-$0.39 (-7.33%)
Updated
Nov 13 closing price
Capitalization
27.48M
Intraday BUY SELL Signals
LIMN
Price
$1.07
Change
-$0.10 (-8.55%)
Updated
Nov 13 closing price
Capitalization
N/A
Intraday BUY SELL Signals
Interact to see
Advertisement

HIND vs LIMN

Header iconHIND vs LIMN Comparison
Open Charts HIND vs LIMNBanner chart's image
Vyome Holdings
Price$4.93
Change-$0.39 (-7.33%)
Volume$32.02K
Capitalization27.48M
Liminatus Pharma
Price$1.07
Change-$0.10 (-8.55%)
Volume$209.43K
CapitalizationN/A
HIND vs LIMN Comparison Chart in %
HIND
Daily Signal:
Gain/Loss:
LIMN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HIND vs. LIMN commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIND is a Hold and LIMN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (HIND: $4.93 vs. LIMN: $1.07)
Brand notoriety: HIND and LIMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HIND: 8% vs. LIMN: 28%
Market capitalization -- HIND: $27.48M vs. LIMN: $0
HIND [@Biotechnology] is valued at $27.48M. LIMN’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HIND’s FA Score shows that 1 FA rating(s) are green whileLIMN’s FA Score has 1 green FA rating(s).

  • HIND’s FA Score: 1 green, 4 red.
  • LIMN’s FA Score: 1 green, 4 red.
According to our system of comparison, HIND is a better buy in the long-term than LIMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HIND’s TA Score shows that 3 TA indicator(s) are bullish while LIMN’s TA Score has 3 bullish TA indicator(s).

  • HIND’s TA Score: 3 bullish, 4 bearish.
  • LIMN’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, LIMN is a better buy in the short-term than HIND.

Price Growth

HIND (@Biotechnology) experienced а -12.90% price change this week, while LIMN (@Biotechnology) price change was -16.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HIND YTD gains are higher at: 19.283 vs. LIMN (-89.572).
HINDLIMNHIND / LIMN
Capitalization27.5MN/A-
EBITDAN/AN/A-
Gain YTD19.283-89.572-22%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
HIND: Fundamental Ratings
HIND
OUTLOOK RATING
1..100
86
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HINDLIMN
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
41%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
35%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
14%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
25%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
31%
Advances
ODDS (%)
Bullish Trend 18 days ago
86%
Bullish Trend 18 days ago
43%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 8 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
40%
View a ticker or compare two or three
Interact to see
Advertisement
HIND
Daily Signal:
Gain/Loss:
LIMN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIXT4.750.34
+7.71%
Lixte Biotechnology Holdings
AON350.110.18
+0.05%
Aon plc
ECG99.59-0.42
-0.42%
Everus Construction Group Inc.
HUMA1.25-0.03
-2.34%
Humacyte
USPH72.53-1.86
-2.50%
US Physical Therapy

HIND and

Correlation & Price change

A.I.dvisor tells us that HIND and CRVS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIND and CRVS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
+0.19%
CRVS - HIND
30%
Poorly correlated
+0.12%
ACET - HIND
20%
Poorly correlated
+6.24%
RNTX - HIND
4%
Poorly correlated
-2.68%
YDES - HIND
3%
Poorly correlated
N/A
LIMN - HIND
2%
Poorly correlated
+0.43%
More

LIMN and

Correlation & Price change

A.I.dvisor tells us that LIMN and AIM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIMN and AIM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIMN
1D Price
Change %
LIMN100%
+0.43%
AIM - LIMN
29%
Poorly correlated
+0.32%
SGMT - LIMN
27%
Poorly correlated
+3.76%
LYEL - LIMN
23%
Poorly correlated
+2.20%
BGMSP - LIMN
23%
Poorly correlated
+4.90%
ALT - LIMN
22%
Poorly correlated
-1.17%
More